Therapeutic novelties in migraine: new drugs, new hope?

被引：92
|
作者：
Thien Phu Do [1 ,2 ]
Guo, Song [1 ,2 ]
Ashina, Messoud [1 ,2 ]
机构：
[1] Univ Copenhagen, Fac Hlth Sci, Rigshosp Glostrup, Danish Headache Ctr, Copenhagen, Denmark
[2] Univ Copenhagen, Fac Hlth Sci, Rigshosp Glostrup, Dept Neurol, Copenhagen, Denmark
来源：
JOURNAL OF HEADACHE AND PAIN | 2019年 / 20卷 / 1期
关键词：
Migraine; Randomized clinical trial; Efficacy; Tolerability; Adverse event; Ditan; Gepant; Antibody; CYCLASE-ACTIVATING POLYPEPTIDE; GENE-RELATED PEPTIDE; DOUBLE-BLIND; SPINAL-CORD; AGONIST; RECEPTOR; SUMATRIPTAN; EXPRESSION; EFFICACY; PROFILE;
D O I：
10.1186/s10194-019-0974-3
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
BackgroundIn the past decade, migraine research has identified novel drug targets. In this review, we discuss recent data on emerging anti-migraine therapies.Main bodyThe development of ditans, gepants and anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of migraine is one of the greatest advances in themigraine field. Lasmiditan, rimegepant and ubrogepant will extend our therapeutic armamentarium for managing acute migraine attacks when triptans are not effective or contraindicated due to cardiovascular disorders. The monoclonal antibodies are migraine specific prophylactic drugs with high responder rates and favorable adverse event profiles. Furthermore, they offer convenient treatment regimens of 4- or 12-week intervals.ConclusionCollectively, novel migraine therapies represent a major progress in migraine treatment and will undoubtedly transform headache medicine.
引用
收藏
页数：13
相关论文
共 50 条
  • [31] A new hope for insulin-sensitizing drugs
    Alan Morris
    Nature Reviews Endocrinology, 2017, 13 : 687 - 687
  • [32] A new hope for insulin-sensitizing drugs
    Morris, Alan
    NATURE REVIEWS ENDOCRINOLOGY, 2017, 13 (12) : 687 - 687
  • [33] Rituximab and nephrotic syndrome: a new therapeutic hope
    Ahmed, Muhammad Shahed
    Wong, Christopher F.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (01) : 11 - 17
  • [34] Is there new hope for therapeutic matrix metalloproteinase inhibition?
    Roosmarijn E. Vandenbroucke
    Claude Libert
    Nature Reviews Drug Discovery, 2014, 13 : 904 - 927
  • [35] Apelin, a new therapeutic hope in cardiovascular disease
    Mach, Sambre
    Bouddiaf, Nour Elhouda
    Robin, Philippe
    M S-MEDECINE SCIENCES, 2022, 38 (03): : 324 - 326
  • [36] Is there new hope for therapeutic matrix metalloproteinase inhibition?
    Vandenbroucke, Roosmarijn E.
    Libert, Claude
    NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (12) : 904 - 927
  • [37] CARDIAC-FAILURE - NEW THERAPEUTIC HOPE
    ACAR, J
    ANNALES DE MEDECINE INTERNE, 1985, 136 (03): : 240 - 241
  • [38] CGRP antagonists: hope for a new era in acute migraine treatment
    Schelstraete, Caroline
    Paemeleire, Koen
    ACTA NEUROLOGICA BELGICA, 2009, 109 (04) : 252 - 261
  • [39] New therapeutic approaches for the prevention and treatment of migraine
    Diener, Hans-Christoph
    Charles, Andrew
    Goadsby, Peter J.
    Holle, Dagny
    LANCET NEUROLOGY, 2015, 14 (10): : 1010 - 1022
  • [40] Clinical applications of new therapeutic deliveries in migraine
    Dahlöf, C
    NEUROLOGY, 2003, 61 (08) : S31 - S34
12345